Through activating GSK-3β, actein treatment significantly reduces the levels of fibrosis markers, including α-SMA, COLI, and COLIII, thereby preventing the development of liver fibrosis in high-fat diet-induced mice 101. The gene discussed is ACTA1; the disease is Hepatic fibrosis.